ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Fear of cancer recurrence is associated with higher primary care use after cancer treatment: a survey-administrative health data linkage study.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- How prevalent is fear of cancer recurrence beyond 5 years: a systematic review of validated assessments across tumour types.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Prediction models for fear of cancer recurrence in adults with cancer: a systematic review.Frontiers in oncology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeTo examine the association between fear of cancer recurrence (FCR) and healthcare utilization after completing cancer treatment.
methodsA population-based survey to examine survivors' experiences and needs after completing cancer treatment was administered by the provincial cancer registry as part of a national study. Respondents included Nova Scotian survivors of breast, melanoma, colorectal, prostate, hematologic, and young adult cancers who were 1-3 years post-treatment. FCR was assessed using a single item that captured presence and severity. Survey responses were linked to cancer registry, physicians' claims, hospitalization, and ambulatory care data. The data linkage provided four years of healthcare utilization data for each cancer survivor, beginning 1 year after their cancer diagnosis. The final study cohort were cancer survivors who responded to the survey, had their data linked, completed the FCR survey items, and were alive and cancer-free during the 4-year follow-up period (n = 823). The data were analyzed descriptively and using regression models for count data analysis.
resultsThirty-eight percent of respondents reported FCR. Younger respondents reported higher levels of FCR compared to older respondents: for example, 66.1% of respondents age 18-54 years reported FCR whereas 24.4% of respondents age 75 years and older reported FCR. More females than males reported FCR. Upon adjusted analyses, FCR was associated with 22% higher primary care use after cancer treatment (incidence rate ratio = 1.22, 95% confidence interval = 1.19-1.25, p < 0.0001). No differences were found for specialist visits between those with FCR and those with no FCR (p = 0.366).
conclusionFCR is a highly prevalent ongoing effect for those who complete cancer treatment. Cancer survivors who reported FCR visited their primary care providers more during follow-up care than those without FCR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.